^
Association details:
| Biomarker: | BTK L528W + BTK C481 |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bruton’s tyrosine kinase and phospholipase C-gamma 2 mutational profiles in pooled analysis of patients with chronic lymphocytic leukemia treated with ibrutinib
Published date:
10/06/2023
Excerpt:
Here we evaluate the BTK and PLCG2 somatic mutation status in 419 patients with CLL treated with ibrutinib, including mutations at the BTK L528 locus...Two patients with BTK L528W had co-occurring BTK C481 mutations and achieved partial response to ibrutinib before PD (duration of response: 20 and 60 months, respectively)...
